InMed Pharmaceuticals (INM) Competitors $2.76 +0.03 (+1.10%) Closing price 04:00 PM EasternExtended Trading$2.74 -0.02 (-0.91%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, LEXX, NKGN, and CASIShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), Lexaria Bioscience (LEXX), NKGen Biotech (NKGN), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience NKGen Biotech CASI Pharmaceuticals InMed Pharmaceuticals (NASDAQ:INM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Does the media favor INM or CTXR? In the previous week, Citius Pharmaceuticals had 3 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.32 beat Citius Pharmaceuticals' score of -0.33 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger earnings and valuation, INM or CTXR? InMed Pharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.60M0.73-$7.68M-$12.09-0.23Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Which has more risk & volatility, INM or CTXR? InMed Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Do insiders & institutionals hold more shares of INM or CTXR? 20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is INM or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. Citius Pharmaceuticals' return on equity of -58.63% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-168.87% -107.93% -82.97% Citius Pharmaceuticals N/A -58.63%-37.67% Do analysts prefer INM or CTXR? Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 2,646.11%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryCitius Pharmaceuticals beats InMed Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.34M$2.37B$5.46B$8.92BDividend YieldN/A1.78%5.24%4.04%P/E Ratio-0.238.9127.0120.12Price / Sales0.73499.49380.1493.35Price / CashN/A21.7726.2128.59Price / Book0.134.537.995.57Net Income-$7.68M$31.26M$3.16B$248.40M7 Day Performance-10.68%5.57%3.69%6.04%1 Month Performance-3.83%5.48%2.91%7.69%1 Year Performance-46.78%1.14%34.30%20.97% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.0298 of 5 stars$2.76+1.1%N/A-48.1%$3.34M$4.60M-0.2310Analyst UpgradeCTXRCitius Pharmaceuticals2.4302 of 5 stars$1.59+3.9%$53.00+3,233.3%-84.1%$16.27MN/A0.0020High Trading VolumeRVPHReviva Pharmaceuticals2.2651 of 5 stars$0.38+12.9%$9.00+2,261.6%-68.6%$16.20MN/A-0.485High Trading VolumePMNPromis Neurosciences3.3528 of 5 stars$0.48+0.7%$4.50+830.1%-76.4%$15.70MN/A-9.685Gap DownGOVXGeoVax Labs3.3257 of 5 stars$0.87-9.8%$11.10+1,182.2%-82.1%$15.29M$3.95M-0.2410Analyst DowngradePRPHProPhase Labs0.7853 of 5 stars$0.39+6.6%N/A-86.4%$15.25M$6.77M-0.31130ALLRAllarity Therapeutics1.1228 of 5 stars$1.01+1.0%N/A-84.1%$15.08MN/A0.0010News CoverageHOTHHoth Therapeutics1.4145 of 5 stars$1.17+3.5%$4.00+241.9%+35.6%$14.93MN/A-1.034Analyst UpgradeLEXXLexaria Bioscience2.8585 of 5 stars$0.87+2.5%$7.00+704.6%-68.0%$14.91M$460K-1.477Upcoming EarningsNKGNNKGen BiotechN/A$0.33+37.4%N/A-77.6%$14.83MN/A-0.06N/AGap DownCASICASI Pharmaceuticals4.106 of 5 stars$1.18-1.7%$4.00+239.0%-76.8%$14.76M$28.54M-0.46180Gap DownHigh Trading Volume Related Companies and Tools Related Companies CTXR Alternatives RVPH Alternatives PMN Alternatives GOVX Alternatives PRPH Alternatives ALLR Alternatives HOTH Alternatives LEXX Alternatives NKGN Alternatives CASI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.